雪榕生物
(300511)
| 流通市值：35.92亿 | | | 总市值：41.54亿 |
| 流通股本：5.17亿 | | | 总股本：5.98亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 440,692,931.37 | 2,162,449,367.04 | 1,641,052,971.34 | 1,070,868,016.87 |
| 营业收入 | 440,692,931.37 | 2,162,449,367.04 | 1,641,052,971.34 | 1,070,868,016.87 |
| 二、营业总成本 | 440,694,795.18 | 2,368,964,063.48 | 1,812,691,932.39 | 1,220,359,916 |
| 营业成本 | 374,560,312.56 | 2,084,497,171.57 | 1,603,496,917.96 | 1,066,559,065.44 |
| 税金及附加 | 4,770,388.17 | 20,290,577.71 | 16,227,428.74 | 11,199,479.63 |
| 销售费用 | 4,529,080.62 | 26,706,501 | 22,120,937.77 | 15,656,983.71 |
| 管理费用 | 35,523,181.47 | 139,068,237.46 | 96,570,903.9 | 64,712,226.47 |
| 研发费用 | 505,920.27 | 3,462,133.88 | 2,994,275.99 | 2,251,021.28 |
| 财务费用 | 20,805,912.09 | 94,939,441.86 | 71,281,468.03 | 59,981,139.47 |
| 其中:利息费用 | 19,104,464.69 | 98,207,748.29 | 74,726,173.22 | 51,424,854.79 |
| 其中:利息收入 | 77,642.78 | 2,472,980.16 | 1,943,393.51 | 1,440,878.38 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | - | -645,524.3 | - | - |
| 资产处置收益 | 8,712,266.5 | 7,850,323.36 | 8,370,860.22 | 8,187,783.49 |
| 资产减值损失(新) | - | -419,434,378.42 | - | - |
| 信用减值损失(新) | -161,079.75 | -6,757,595.94 | -624,425.34 | -408,725.3 |
| 其他收益 | 3,450,029.09 | 11,681,732.88 | 8,688,181.01 | 4,797,713.55 |
| 四、营业利润 | 11,999,352.03 | -613,820,138.86 | -155,204,345.16 | -136,915,127.39 |
| 加:营业外收入 | 273,676.28 | 1,790,900.2 | 970,676.49 | 605,600.75 |
| 减:营业外支出 | 24,998.43 | 4,376,957.26 | 1,091,882.1 | 796,871.83 |
| 五、利润总额 | 12,248,029.88 | -616,406,195.92 | -155,325,550.77 | -137,106,398.47 |
| 减:所得税费用 | 5.63 | 66.28 | 66.28 | 39.39 |
| 六、净利润 | 12,248,024.25 | -616,406,262.2 | -155,325,617.05 | -137,106,437.86 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 12,248,024.25 | -616,406,262.2 | -155,325,617.05 | -137,106,437.86 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 7,242,399.82 | -617,070,813.21 | -163,809,859.67 | -143,594,085.68 |
| 少数股东损益 | 5,005,624.43 | 664,551.01 | 8,484,242.62 | 6,487,647.82 |
| 扣除非经常损益后的净利润 | -4,839,350.95 | -634,007,117.72 | -180,303,482.66 | -156,485,398.79 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.01 | -1.24 | -0.33 | -0.29 |
| (二)稀释每股收益 | 0.01 | -1.24 | -0.33 | -0.29 |
| 八、其他综合收益 | -61,046.09 | 1,653,157.21 | 387,936.84 | 150,330.82 |
| 归属于母公司股东的其他综合收益 | -50,838.5 | 996,197.65 | 276,407.24 | 42,222 |
| 九、综合收益总额 | 12,186,978.16 | -614,753,104.99 | -154,937,680.21 | -136,956,107.04 |
| 归属于母公司股东的综合收益总额 | 7,191,561.32 | -616,074,615.56 | -163,533,452.43 | -143,551,863.68 |
| 归属于少数股东的综合收益总额 | 4,995,416.84 | 1,321,510.57 | 8,595,772.22 | 6,595,756.64 |
| 公告日期 | 2025-04-28 | 2025-04-28 | 2024-10-25 | 2024-08-29 |
| 审计意见(境内) | | 标准无保留意见 | | |